Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 studyKevin H.M. Kuo, Elliott Vichinsky, Tong Bo et al.|The Lancet|2022Cited by 87
Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2021Cited by 7
S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIAKevin H.M. Kuo, Elliott Vichinsky, K Uhlig et al.|HemaSphere|2022Cited by 1